UV 4B

Drug Profile

UV 4B

Alternative Names: UV 4; UV-4B

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synergy Pharmaceuticals Inc; University of Oxford
  • Developer Emergent BioSolutions; United Therapeutics Corporation
  • Class Antivirals; Imino sugars; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dengue
  • Preclinical Influenza virus infections

Most Recent Events

  • 02 Mar 2017 Emergent BioSolutions terminates a phase I trial in Healthy volunteers in USA (NCT02696291)
  • 17 Feb 2017 Emergent BioSolutions suspends a phase I trial in Healthy volunteers in USA (NCT02696291)
  • 30 May 2016 Preclinical trials in Influenza virus infections in USA (PO) before May 2016 (Emergent BioSolutions 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top